26 Feb 2024: Nona Biosciences and Boostimmune unite for Cutting-edge ADC development
Nona Biosciences, a global biotechnology company, collaborates with Boostimmune to expedite Antibody-Drug Conjugates development using Harbour Mice H2L2 platform for innovative cancer therapies
Harbour Mice generates fully human mAbs in classical two light and two heavy chains (H2L2) format, and heavy chain only (HCAb) format
Integrating Harbour Mice and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs
Boostimmune was co-founded in 2021 by Professor Tadatsugu Taniguchi, who originally identified interferon beta, interleukin-2, and interferon regulatory factors (IRFs)